Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Real Time Quote from BATS)

$5.80 USD

5.80
1,383,914

+0.12 (2.11%)

Updated Jul 31, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Options Traders Expect Huge Moves in Aurinia (AUPH) Stock

by Zacks Equity Research

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Options Traders Expect Huge Moves in Aurinia (AUPH) Stock

by Zacks Equity Research

Investors need to pay close attention to Aurinia (ENPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -13.33% and -45.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?

      by Zacks Equity Research

      Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

        Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

        by Zacks Equity Research

        Aurinia Pharmaceuticals (AUPH) needs Investors to pay close attention to the stock based on moves in the options market lately.

          Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session

          by Zacks Equity Research

          Aurinia Pharmaceuticals saw its shares rise nearly 8% on the day.

            Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?

            by Zacks Equity Research

            Investors certainly have to be happy with Aurinia Pharmaceuticals Inc (AUPH) and its short term performance

              Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock

              by Zacks Equity Research

              Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock on the back of its high implied volatility

                Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?

                by Zacks Equity Research

                Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately.

                  Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

                  by Zacks Equity Research

                  Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

                    Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?

                    by Zacks Equity Research

                    Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH) may be one such company.

                      What's in the Cards for Repros (RPRX) this Earnings Season?

                      by Zacks Equity Research

                      Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.

                        Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?

                        by Zacks Equity Research

                        Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.